Amneal Pharmaceuticals has launched oseltamivir phosphate
for oral suspension, the company's AB-rated therapeutic equivalent for Tamiflu, in a 6 mg/mL strength.
Tenders are invited for Substance Oseltamivir phosphate
(Mandatory requirements for the substance: manufacturer Cipla Ltd, India - ND RB 0901 S-2015)
is intended for use in patients 2 weeks of age and older who have had flu symptoms for no more than 48 hours, and for prevention of influenza in patients 1 year of age and older.
The most common side effects reported by patients using oseltamivir phosphate
in clinical trials included nausea and vomiting.
According to the company, Influenza A H1N1 infected animals treated with FluCide survived the full 21-day observation period, whereas animals treated with 40mg/kg/d oseltamivir phosphate
(Tamiflu) survived only eight days in this highly lethal study.
Food and Drug Administration (FDA) approved oseltamivir phosphate
(Tamiflu[R]) for treatment in children as young as two weeks old (FDA, 2012).
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate
treatment leave virus severely compromised both in vitro and in vivo.
Tamiflu is the brand name for oseltamivir phosphate
Tamiflu is the trade name for oseltamivir phosphate
Of the total 40 million doses of Tamiflu, or Oseltamivir phosphate
, 20 million doses have already been used up.
, marketed as Tamiflu, is a popular neuraminidase inhibitor widely used to treat flu symptoms.
The only drugs approved for the prevention and treatment of swine flu are oseltamivir phosphate
(Tamiflu) and zanamivir (Relenza).